multiple sclerosis

Janssen files MS pill, ahead of FDA decision on BMS’ rival
Pharmaforum
Thu, 03/19/20 - 11:06 am
Janssen
JNJ
multiple sclerosis
MS
FDA
ponesimod
Bristol-Myers Squibb
ozanimod
France’s MedDay says drug for MS falls at phase 3 hurdle
Pharmaforum
Thu, 03/12/20 - 10:54 am
MedDay Pharma
France
MD1003
multiple sclerosis
MS
clinical trials
Go or no go? Ozanimod and Fintepla await FDA verdicts
EP Vantage
Wed, 02/26/20 - 10:26 am
Bristol-Myers Squibb
ozaminod
MS
multiple sclerosis
Zogenix
Fintepla
FDA
Teva Calls on FDA to Make Copaxone a Biologic as Part of March Transition
RAPS.org
Mon, 02/24/20 - 11:47 pm
Teva Pharmaceutical
Copaxone
MS
multiple sclerosis
FDA
biologics
Novartis gets a boost in blockbuster multiple sclerosis race with Roche
Endpoints
Mon, 02/24/20 - 10:41 am
Novartis
MS
multiple sclerosis
FDA
priority reviews
Arzerra
To challenge Ocrevus, German Merck takes on Aubagio
EP Vantage
Sun, 02/23/20 - 02:00 pm
Ocrevus
Merck KGaA
Aubagio
evobrutinib
MS
multiple sclerosis
Will Biogen’s Big Patent Victory Ease Investor Worries About Its Alzheimer’s Drug?
Motley Fool
Tue, 02/11/20 - 10:36 am
Biogen
Mylan
Alzheimer's disease
patents
Tecfidera
MS
multiple sclerosis
Vumerity
Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis
BioSpace
Sun, 02/9/20 - 04:01 pm
MS
multiple sclerosis
Biogen
Sanofi
Active Biotech
Mylan
Novartis
Adamas
Multiple sclerosis “win” makes the Principia shorts squirm
EP Vantage
Thu, 02/6/20 - 10:51 am
Principia Biopharma
SAR442168
MS
multiple sclerosis
Biogen wins Tecfidera patent challenge from Mylan, sending shares way up
Fierce Pharma
Wed, 02/5/20 - 10:25 pm
Biogen
patents
Tecfidera
Mylan
multiple sclerosis
MS
Active Biotech is back, with one last bid for the failed MS drug Teva discarded
Endpoints
Wed, 02/5/20 - 10:11 am
Teva Pharmaceutical
Active Biotech
laquinimod
MS
multiple sclerosis
GeNeuro raises €17.5M for multiple sclerosis clinical trial
Fierce Biotech
Fri, 01/31/20 - 12:18 pm
GeNeuro
MS
multiple sclerosis
clinical trials
temelimab
Patients Still Struggle To Balance High Costs Of MS Treatment, Despite Generic
NPR
Mon, 01/20/20 - 10:56 am
drug pricing
generics
MS
multiple sclerosis
New MS Trial Will be First to Compare Stem Cell Therapy with Best Available Biologics
Xtalks
Mon, 01/13/20 - 11:35 pm
stem cells
MS
multiple sclerosis
NIH
AHSCT
Biogen
Tysabri
Sanofi
Lemtrada
Roche
Ocrevus
Rituxan
Pear Therapeutics announces first patient dosed in part II of Pear-006 feasibility study
Pharmaceutical Business Review
Wed, 12/18/19 - 10:31 am
Pear Therapeutics
MS
multiple sclerosis
Pear-006
clinical trials
While Novartis combats generic onslaught in the courts, FDA approves first Gilenya copycats
Endpoints
Fri, 12/6/19 - 09:54 am
Novartis
FDA
Gilenya
MS
multiple sclerosis
Mylan
Dr Reddy's
Torrent Pharmaceuticals
Aurobindo
generics
Treating multiple sclerosis with the help of the gut microbiome
Fierce Biotech
Mon, 12/2/19 - 09:58 am
Brigham and Women's
microbiome
microRNA
multiple sclerosis
MS
Patient charity to pay $4M to settle kickback allegations
Beckers Hospital Review
Fri, 11/22/19 - 10:12 am
kickbacks
Medicare
Medicare fraud
MS
multiple sclerosis
Teva Pharmaceutical
Biogen
Novartis
Novartis, Merck KGaA and Biogen: Which new MS drug do doctors like best? You might be surprised
Fierce Pharma
Tue, 11/19/19 - 02:41 pm
MS
multiple sclerosis
physicians
Novartis
Mayzent
Merck KGaA
Mavenclad
Biogen
Vumerity
Vumerity’s $88,000 List Price Not What ‘We Had Hoped,’ National MS Society Says
Multiple Sclerosis News Today
Thu, 11/14/19 - 07:35 pm
Biogen
MS
multiple sclerosis
Vumerity
drug pricing
Tecfidera

Pages